. 2021 Jun 8;36(3):582–589. doi: 10.3803/EnM.2021.983

Table 3.

Thyroid Function and Antibody Profile of Patients with New-Onset Anti-Thyroid Peroxidase Antibody Positivity

Patient no.	On admission						COVID-19 treatment	Reassessment

	TSH, mIU/L^a	fT4, pmol/L^a	fT3, pmol/L^a	Anti-TPO, U^b	Anti-Tg, U^b	Anti-TSHR, IU/L^b		Days	TSH, mIU/L^a	fT4, pmol/L^a	fT3, pmol/L^a	Anti-TPO, U^b	Anti-Tg, U^b	Anti-TSHR, IU/L^b
21	1.2	17	3.5	6.85	4.90	1.6^c	IFN+RIB	93	2.8	20	5.0	141.24^c	8.31	1.2^c

22	1.3	18	NA	45.45	4.31	1.0	IFN+RIB	89	1.7	17	5.3	148.21^c	6.58	1.4^c

23	2.2	16	4.6	97.06	4.84	0.2	IFN+RIB	90	1.7	20	5.6	122.37^c	7.31	1.2^c

24	1.1	17	4.4	99.85	6.62	0.7	IFN+RIB	105	0.47	19	5.2	128.51^c	9.67	0.7

TSH, thyroid-stimulating hormone; fT4, free thyroxine; fT3, free triiodothyronine; TPO, thyroid peroxidase; Tg, thyroglobulin; TSHR, TSH receptor antibody; COVID-19, coronavirus disease 2019; IFN, interferon beta-1b; RIB, ribavirin.

Reference ranges: TSH 0.35–4.8 mIU/L, fT4 12–23 pmol/L, fT3 3.2–6.5 pmol/L;

Positive anti-TPO defined as >100 U, positive anti-Tg defined as >100 U, positive anti-TSHR defined as >1 IU/L;

Values out of the reference ranges.